New Publication in Science Shows That Agios Pharmaceuticals' IDH1 Inhibitor Can Reverse Cancer-Causing Effects of Oncometabolite 2-HG in Leukemia Model
2/13/2013 11:19:23 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Agios Pharmaceuticals, Inc., the leading biopharmaceutical company focused on discovering and developing novel drugs in the fields of cancer metabolism and rare metabolic genetic diseases, announced today a recent publication of research from Agios collaborator and scientific advisor William G. Kaelin, Jr., M.D., of the Dana-Farber Cancer Institute, Brigham and Women's Hospital, and the Dana-Farber/Harvard Cancer Center, that demonstrates the cancer-causing effects of the oncometabolite 2-hydroxyglutarate (2-HG) in a leukemia cell model. Notably, these effects were reversible when treated with an isocitrate dehydrogenase 1 (IDH1) inhibitor discovered, developed and provided by Agios, which blocks the production of 2-HG. The article “(R)-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible” was published in Science online on February 7, 2013.
comments powered by